Hemangioblastoma - 4 Studies Found

Terminated : Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow
:
  • Von Hippel-Lindau Syndrome
  • Renal Cell Carcinoma
  • : 2006-05-26
    : Drug: SU011248 50 mg/day orally for 4 weeks, no treatment for 2 weeks (6 weeks = 1 cycle).
Completed : Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
:
  • CNS Cancer
  • Meningioma
  • Intracranial Hemangiopericytoma

    • : 2007-12-26
    : Drug: Sunitinib The study drug will be administered on an outpatient basis. The starting dose will be 50
Completed : Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease
:
  • Von Hippel-Lindau Disease
  • Hemangioblastoma
  • Deafness
  • Kidney Diseases
  • Kidney Neoplasms